GenOway: Euroland initiates buy coverage

(CercleFinance.com) - On Wednesday, Euroland initiated coverage of genOway shares with a Buy recommendation and a price target of 5.
80 euros, representing a 41% upside potential.

In a research note, the brokerage firm praises the transformation carried out by the company since 2018, which has notably enabled it to accelerate growth and improve margins via an adjustment of its business model.

Long presented as a biotech company, genOway is in fact a provider of innovative solutions for biopharmaceutical companies and their preclinical research", emphasizes the market intermediary.

Indeed, the company designs and develops genetically modified research models enabling better prediction of patient response to future treatments', continues Euroland.

According to the analyst, this positioning enables the company's clients to accelerate and make more reliable the processes involved in bringing innovative therapies to market.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.